Skip to main content
Premium Trial:

Request an Annual Quote

Accelerate Raises $20M in Rights Offering

NEW YORK (GenomeWeb News) – Accelerate Diagnostics today said it has completed a previously announced rights offering, raising $20 million.

The offering had broad participation from insiders and non-insider investors and included a standby commitment by Abeja Ventures.

Stockholders subscribed for a total of about 1.9 million shares, pursuant to their basic subscription privileges, for a participation rate of 75 percent. Shareholders also over-subscribed for a total of 1.1 million shares of which 203,062 shares were issued after exclusions based on the outcome of the basic subscription, the Tucson, Ariz.-based firm said.

A total of 413,090 shares will be issued to Abeja. In aggregate Accelerate will issue almost 2.5 million shares of its common stock, of which 1.7 million shares, or 69 percent, were acquired by company directors.

The company has said that net proceeds will go toward working capital and funding of Accelerate's business plan and product commercialization work.

On Monday, the company reported a 68 percent reduction in revenues for its second quarter.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.